Media & Press Updates


Israel Biotech Fund

We are excited to step into 2022 together with #IBF
Proud to be part of exclusive portfolio of innovative #lifesciences companies.
This #funding accelerates the path towards clinical stage of our #first-in-class #biotherapy targeting #cancers with #p53 mutations.
We are on mission to bring #cure to cancer patients.

December 31, 2021

Medinvest Oncology virtual conference.jpg

Virtual MedInvest Oncology Investor Conference

This week ExoProTher Medical presented at the virtual MedInvest Oncology Investor Conference. ExoProTher’s Chief Executive Officer, Lana Volokh, delivered the corporate overview.  She described the Company’s unique scientific foundation and technology and provided an update on program status. ExoProTher aims to significantly impact the way cancer is treated. Link to the presentation recording: .


December 11, 2021


PAT-ICRS workshop

Presenting our latest results at the PAT-ICRS workshop.


Watch on YouTube

October 7th, 2021


In lab Investors event

Investors event in our R&D Lab at Colab square Yokneam, taking a glimpse into the digital microscope along with markers on milestones achieved.

July 9th, 2021


New R&D lab at Colab Square Facility, Yokneam

Beginning May 2021, ExoProTher is operating a new R&D lab situated at unique Colab Square facility in Yokneam Industrial park. ExoProTher is joining a line of exciting and promising biotech companies.

The combination of location, equipment and environment allow to boost R&D activities and attract top talent to the expanding team.

June 24, 2021


2021 Virtual World Stem Cell Summit

ExoProTher Medical - Co-founder & CEO Dr. Lana Volokh
at The Investor Forum - at the 2021 Virtual World Stem Cell Summit. (hosted by channelchek)

June 17th, 2021


SEV2021 Annual Meeting

ExoProTher's scientific abstract reporting our recent preclinical results at the Annual Meeting of International Society for Extracellular Vesicles.

May 18-21, 2021

r_Magische kugel against cancer abstract

Magische kugel against cancer

"Magic bullet against cancer"

Short Communication - Journal of Molecular Oncology Research (2021) Volume 5, Issue 2

March 10th, 2021

ExoProTher Globes.png

New media coverage - Globes article featuring ExoProTher

ExoProTher article in Israeli business daily the "Globes".

Hebrew article by Globes' biomed reporter, Gali Weinreb.

January 6th, 2021


Startup World Cup

ExoProTher is honored to be selected among top ten Israeli companies in the largest startup competition in the world - Startup World Cup.


Best regards,

Lana Volokh - CEO

January 5th, 2021


ExoProTher milestone achieved

I am pleased to share with our followers and investors the latest in vivo results.

Two weeks ago, a successful in vivo experiment on mouse model of colon cancer ended with impressive results. Life span of treated mice was significantly prolonged after single dose of Exo, while 25% of them remained tumor-free after the experiment completion. Additional in vivo studies using other cancer models are in progress.


Best regards,

Lana Volokh - CEO

November 12, 2020

r_ExoProTher new recruites.jpg

New recruits & Additional facility

Exciting growth period for ExoProTher Medical: we opened a new laboratory facility and brought on board new talent.


The new laboratory started functioning in Shlomi, Israel. It will focus on optimizing production and characterization of EXO_ compounds. 


With extended R&D team, we continue to broaden and deepen our research capabilities.

September 13, 2020

r_SoCal super position.jpg

Startup Day

Velocity on the rise not only in our labs.

Great boost coming from amazing crowd engagement in the SoCal startup event.

February 26, 2020


Startup Day

We are excited to attend the SoCal Startup Day and present our development.
Come see our quick-fire presentation as part of the start-up competition and visit us at booth #22 to learn more about our unique approach.

February 26, 2020

r_Interview - Tel-Aviv stock

@Tel-Aviv stock exchange

ExitValley and Eternity Capital investors event at the Tel-Aviv stock exchange.

February 5, 2020


Call for Action

ExoProTher VP Business Development update and call for action.

December 12, 2019


ExitValley's campaign

About a week into the campaign and the traction is high,

More than 100% of initial funding target. 

December 9, 2019

ExitValley's Investors meeting

What a great event to be part of – first ExitValley’s Investors meeting!

Dr. Alex Tendler, co-founder and CTO of ExoProTher Medical, presented our unique concept and its outstanding potential to the very interested audience.

Excellent traction, 

ExoProTher Medical launched the crowdfunding campaign using ExitValley platform.

It is super cool to see first investment after less than 12 hours. Amazing start.

December 2, 2019


TheMarker's OncoTalk